Johnson & Johnson (JNJ)vsOmniAb Inc. (OABI)
JNJ
Johnson & Johnson
$273.20
-0.73%
HEALTHCARE · Cap: $657.68B
OABI
OmniAb Inc.
$5.11
-2.29%
HEALTHCARE · Cap: $677.52M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 258201% more annual revenue ($99.33B vs $38.46M). JNJ leads profitability with a 16.2% profit margin vs -115.1%. JNJ earns a higher WallStSmart Score of 54/100 (C-).
JNJ
Buy54
out of 100
Grade: C-
OABI
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-89.3%
Fair Value
$144.28
Current Price
$273.20
$128.92 premium
Intrinsic value data unavailable for OABI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Revenue surging 244.2% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Trading at 8.1x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -17.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bull Case : OABI
The strongest argument for OABI centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 244.2% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Bear Case : OABI
The primary concerns for OABI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while OABI is a hypergrowth play — different risk/reward profiles.
OABI carries more volatility with a beta of 1.37 — expect wider price swings.
OABI is growing revenue faster at 244.2% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 37/100), backed by strong 16.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →OmniAb Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. This proprietary technology enables the rapid identification and optimization of effective therapies across various disease areas, thereby enhancing the likelihood of successful clinical outcomes. By establishing strategic partnerships and collaborations, OmniAb streamlines its drug development processes and improves access to groundbreaking treatments. Supported by a seasoned leadership team and a robust pipeline of product candidates, the company is strategically positioned to capitalize on the growing opportunities within the biopharmaceutical industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?